Last Posted: May 31, 2019
- P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.
Povsic Thomas J et al. JAMA cardiology 2019 May - NR3C1 , ABCB1 , TNF and CYP2C19 polymorphisms association with the response to the treatment of erythema nodosum leprosum.
do Socorro Silva Costa Perpétua et al. Pharmacogenomics 2019 May 20(7) 503-516 - Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer.
Hannouf Malek B et al. The pharmacogenomics journal 2019 May - Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial.
Zhang Xiao-Guang et al. BMJ open 2019 May 9(5) e028595 - The Pharmacogenetics of Natural Products: A Pharmacokinetic and Pharmacodynamic Perspective.
Rao Tai et al. Pharmacological research 2019 May 104283 - 4th ESPT summer school: precision medicine and personalised health.
Mlakar Vid et al. Pharmacogenomics 2019 May 20(7) 471-474 - Continuous pharmacogenomics and genomic medicine education for healthcare professionals through electronic educational courses.
Tsermpini Evangelia-Eirini et al. Personalized medicine 2019 May - Are privacy-enhancing technologies for genomic data ready for the clinic? A survey of medical experts of the Swiss HIV Cohort Study.
Raisaro Jean-Louis et al. Journal of biomedical informatics 2018 791-6 - Genomics and electronic health record systems.
Ohno-Machado Lucila et al. Human molecular genetics 2018 27(R1) R48-R55 - Pharmacogenomics and variations in the risk of toxicity during the consolidation/maintenance phases of the treatment of pediatric B-cell leukemia patients from an admixed population in the Brazilian Amazon.
de Carvalho Darlen Cardoso et al. Leukemia research 2018 7410-13
.png)
No hay comentarios:
Publicar un comentario